{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-QD381EEE/31707f5c-163b-42d2-9ecb-8f537974df50/PDF","dcterms:extent":"384 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-QD381EEE/2bc2dc72-6e77-40af-84d8-23e28577f250/TEXT","dcterms:extent":"47 KB"}],"edm:TimeSpan":{"@rdf:about":"2005-2025","edm:begin":{"@xml:lang":"en","#text":"2005"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-QD381EEE","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN"},{"@xml:lang":"sl","#text":"Farmacevtski vestnik"}],"dcterms:issued":"2025","dc:creator":"Groti Antonič, Kristina","dc:format":[{"@xml:lang":"sl","#text":"številka:2"},{"@xml:lang":"sl","#text":"letnik:76"},{"@xml:lang":"sl","#text":"str. 99-108"}],"dc:identifier":["COBISSID_HOST:242346243","ISSN:2536-4316","URN:URN:NBN:SI:doc-QD381EEE"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"dc:subject":[{"@xml:lang":"sl","#text":"debelost"},{"@xml:lang":"en","#text":"menopause"},{"@xml:lang":"sl","#text":"menopavza"},{"@xml:lang":"en","#text":"metabolic syndrome"},{"@xml:lang":"sl","#text":"metabolni sindrom"},{"@xml:lang":"en","#text":"metformi"},{"@xml:lang":"sl","#text":"metformin"},{"@xml:lang":"en","#text":"obesity"},{"@xml:lang":"sl","#text":"sladkorna bolezen tipa 2"},{"@xml:lang":"en","#text":"type 2 diabetes"}],"dcterms:temporal":{"@rdf:resource":"2005-2025"},"dc:title":{"@xml:lang":"sl","#text":"Menopavza in metabolni sindrom| Menopause and metabolic syndrome|"},"dc:description":[{"@xml:lang":"sl","#text":"Metabolic syndrome is a cluster of associated clinical and metabolic risk factors that predict the risk of type 2 diabetes and cardiovascular disease. Metabolic Syndrome includes visceral obesity, impaired glucose metabolism, atherogenic dyslipidemia, and arterial hypertension. The increased prevalence of metabolic syndrome in menopause is due to the loss of the proactive role of estrogens and increased androgens in the circulation, resulting in redistribution of body fat and development of visceral obesity. Metabolic syndrome can also affect the risk of breast and endometrial cancer, osteoporosis, chronic kidney disease, cardiovascular diseases and reduce quality of life during menopause. Intentional weight loss, calorie restric"},{"@xml:lang":"sl","#text":"Metabolni sindrom je skupek povezanih kliničnih in presnovnih dejavnikov, ki napovedujejo tveganje za nastanek sladkorne bolezni tipa 2 in srčno-žilne bolezni. Metabolni sindrom vključuje visceralno debelost, moteno presnovo glukoze, aterogeno dislipidemijo in arterijsko hipertenzijo. Povečana prevalenca metabolnega sindroma v menopavzi je posledica izgube proaktivne vloge estrogenov in povečanih koncentracij androgenov v obtoku, kar povzroči porazdelitev telesne maščobe in razvoj visceralne debelosti. Metabolni sindrom lahko vpliva tudi na tveganje za nastanek raka endometrija in dojke, osteoporoze, kronične ledvične bolezni, srčno-žilnih zapletov ter zmanjšanja kakovosti življenja v menopavzi. Načrtovano hujšanje, omejitev kalorij in telesna aktivnost so povezani z zmanjšanim tveganjem za bolezni endometrija. Poleg sprememb življenjskega sloga se lahko v primeru odsotnosti kontraindikacij predpiše zdravilo metformin, ki zmanjšuje metabolni sindrom, znižuje raven inzulina pri ženskah po menopavzi in je močan zaviralec proliferacije rakavih celic endometrija. Še vedno pa je pri obvladovanju simptomov in nekaterih posledic menopavze najučinkovitejše hormonsko nadomestno zdravljenje"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-QD381EEE","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-QD381EEE"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-QD381EEE/31707f5c-163b-42d2-9ecb-8f537974df50/PDF"},"edm:rights":{"@rdf:resource":"http://creativecommons.org/licenses/by-nc/4.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-QD381EEE/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-QD381EEE"}}}}